PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
HER2-positive Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 466 (final count)
- Started
- Oct 2, 2019
- Main results expected
- Jun 29, 2023
- Fully finished
- Mar 10, 2029
- Results posted
- Jul 30, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment
Measured over: From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03975647 · record last updated 2026-07-23 · checked 2026-11-09 15:42 UTC